true....they are killing medical innovation... ,most of the companies especially small biotech will run our of equity/capital to fund..which will impact research.. wait until they get uncurable cancer!!!....bloody dem·a·gogue
Spoke Friday evening with investor analyst@KMI .. Announce plans for 2016.. Dividend will be frozen , possible some asset sales ..in my view KMI should stabling in low 20s if oil remains in this range..
Remember it was $90 stock in Nov-Dec2014 before Biomarin acquired this useless drug..sales of other drugs have gone up and pipeline advance, so at this point, market is accounting for Zero probability of approval.
Biomarin will trade with IBB biotech index going fwd...it is like 40% down from its summer highs..
I won't be short this stock at this price. mid-90s...not much downside. always a chance of M&A and surprise. it can rip upwards..